Pharmacy Medical News about Lenalidomide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors
Journal of Cancer Research & Clinical Oncology, 09/24/09

Oechsle K et al. – Treatment options are still limited in patients with cisplatin–refractory and multiply relapsed germ cell tumors. Lenalidomide was well tolerated and showed efficacy in heavily pretreated patients with cisplatin–refractory and multiply relapsed germ cell tumors.

<< Previous
Hypoxia induced paclitaxel resistance in human ovarian cancers...

Next >>
The HAART cell phone adherence trial (WelTel Kenya1): a...

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09 Relevance Score: 93%

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09 Relevance Score: 91%

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 11/20/09 Relevance Score: 90%

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 10/02/09 Relevance Score: 89%

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone
Journal of Clinical Oncology, 11/13/09 Relevance Score: 88%